

Eric E Klein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3249191/publications.pdf>

Version: 2024-02-01

321
papers

25,765
citations

10986

71
h-index

7348

152
g-index

331
all docs

331
docs citations

331
times ranked

25558
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life and Satisfaction with Outcome among Prostate-Cancer Survivors. <i>New England Journal of Medicine</i> , 2008, 358, 1250-1261.	27.0	2,030
2	Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 39.	7.4	1,832
3	Vitamin E and the Risk of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1549.	7.4	1,458
4	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
5	Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2007, 25, 2035-2041.	1.6	836
6	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	1.2	770
7	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 869-875.	0.4	574
8	Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 7005-7012.	1.6	564
9	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>European Urology</i> , 2014, 66, 550-560.	1.9	553
10	Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era. <i>Journal of Clinical Oncology</i> , 2009, 27, 4300-4305.	1.6	417
11	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
12	The Surgical Learning Curve for Prostate Cancer Control After Radical Prostatectomy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1171-1177.	6.3	368
13	Cell-Cycle Control by Physiological Matrix Elasticity and In Vivo Tissue Stiffening. <i>Current Biology</i> , 2009, 19, 1511-1518.	3.9	368
14	Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline. <i>Journal of Urology</i> , 2013, 190, 441-449.	0.4	368
15	Hypofractionated Intensity-Modulated Radiotherapy (70 Gy at 2.5 Gy Per Fraction) for Localized Prostate Cancer: Cleveland Clinic Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1424-1430.	0.8	342
16	Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Journal of the National Cancer Institute</i> , 2005, 97, 94-102.	6.3	309
17	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	21.4	294
18	Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. <i>BMC Genomics</i> , 2013, 14, 690.	2.8	277

#	ARTICLE	IF	CITATIONS
19	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
20	Complications of Nephron Sparing Surgery for Renal Tumors. <i>Journal of Urology</i> , 1994, 151, 1177-1180.	0.4	253
21	Prediction of Erectile Function Following Treatment for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1205.	7.4	253
22	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	7.4	252
23	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. <i>Urology</i> , 2015, 85, 101-106.	1.0	241
24	TPR2SS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. <i>Prostate</i> , 2011, 71, 489-497.	2.3	239
25	A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. <i>Nature Genetics</i> , 2013, 45, 690-696.	21.4	232
26	Comparison of the Efficacy of Local Therapies for Localized Prostate Cancer in the Prostate-Specific Antigen Era: A Large Single-Institution Experience With Radical Prostatectomy and External-Beam Radiotherapy. <i>Journal of Clinical Oncology</i> , 2002, 20, 3376-3385.	1.6	230
27	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	10.7	226
28	Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt456.	6.3	221
29	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	7.1	219
30	RETROPERITONEAL LAPAROSCOPIC RADICAL NEPHRECTOMY: THE CLEVELAND CLINIC EXPERIENCE. <i>Journal of Urology</i> , 2000, 163, 1665-1670.	0.4	212
31	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. <i>Journal of Urology</i> , 2014, 192, 1081-1087.	0.4	196
32	Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 1160-1167.	1.9	192
33	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	12.8	188
34	Time to initial cancer treatment in the United States and association with survival over time: An observational study. <i>PLoS ONE</i> , 2019, 14, e0213209.	2.5	179
35	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2017, 35, 1991-1998.	1.6	176
36	A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy. <i>European Urology</i> , 2015, 67, 778-786.	1.9	162

#	ARTICLE	IF	CITATIONS
37	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-590.	1.6	162
38	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2591-2600.	7.0	157
39	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	1.6	155
40	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. <i>Cancer Research</i> , 2016, 76, 4948-4958.	0.9	147
41	Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration. <i>Journal of Clinical Oncology</i> , 1999, 17, 3167-3172.	1.6	142
42	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. <i>Journal of the National Cancer Institute</i> , 2019, 111, 301-310.	6.3	142
43	Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1474-1494.	1.6	141
44	Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2004, 63, 1138-1142.	1.0	140
45	SELECT: the selenium and vitamin E cancer prevention trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003, 21, 59-65.	1.6	138
46	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. <i>Urology</i> , 2016, 90, 148-152.	1.0	138
47	Extent of extracapsular extension in localized prostate cancer. <i>Urology</i> , 2000, 55, 382-386.	1.0	136
48	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	6.1	132
49	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2789-2796.	1.6	127
50	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	16.8	127
51	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	1.9	125
52	A Multi-Institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2009, 181, 1635-1641.	0.4	121
53	Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. <i>BJU International</i> , 2011, 107, 765-770.	2.5	120
54	Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv431.	6.3	111

#	ARTICLE	IF	CITATIONS
55	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. <i>Lancet Oncology</i> , 2016, 17, 1435-1444.	10.7	107
56	Early Continence after Radical Prostatectomy. <i>Journal of Urology</i> , 1992, 148, 92-95.	0.4	106
57	Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2001, 57, 281-285.	1.0	103
58	PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60408.	2.5	102
59	The Selenium and Vitamin E Cancer Prevention Trial. <i>World Journal of Urology</i> , 2003, 21, 21-27.	2.2	100
60	Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. <i>PLoS Genetics</i> , 2017, 13, e1006719.	3.5	98
61	MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. <i>Cancer Research</i> , 2017, 77, 1021-1034.	0.9	94
62	Selenium: Epidemiology and Basic Science. <i>Journal of Urology</i> , 2004, 171, S50-3; discussion S53.	0.4	93
63	Update on chemoprevention of prostate cancer. <i>Current Opinion in Urology</i> , 2004, 14, 143-149.	1.8	93
64	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	1.8	88
65	Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. <i>Urology</i> , 2006, 67, 1253-1256.	1.0	86
66	Lack of pathologic downstaging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2009, 115, 792-799.	4.1	85
67	Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. <i>ELife</i> , 2017, 6, .	6.0	83
68	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015, 194, 297-303.	0.4	80
69	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. <i>European Urology</i> , 2016, 70, 14-17.	1.9	79
70	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. <i>European Urology</i> , 2017, 72, 845-852.	1.9	79
71	Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer-specific Mortality. <i>European Urology</i> , 2014, 65, 675-680.	1.9	77
72	Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. <i>Cancer</i> , 2009, 115, 1005-1010.	4.1	71

#	ARTICLE	IF	CITATIONS
73	Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. <i>European Urology</i> , 2013, 64, 372-378.	1.9	71
74	Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 164-169.	0.8	69
75	Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. <i>Scientific Reports</i> , 2021, 11, 11130.	3.3	68
76	The Epstein Criteria Predict for Organ-Confined But Not Insignificant Disease and a High Likelihood of Cure at Radical Prostatectomy. <i>European Urology</i> , 2010, 58, 90-95.	1.9	67
77	Five Year Biochemical Recurrence Free Survival for Intermediate Risk Prostate Cancer After Radical Prostatectomy, External Beam Radiation Therapy or Permanent Seed Implantation. <i>Urology</i> , 2010, 76, 1251-1257.	1.0	64
78	Management of erectile dysfunction following radical prostatectomy. <i>Current Urology Reports</i> , 2001, 2, 495-503.	2.2	63
79	Long-Term Efficacy and Toxicity of Low-Dose-Rate 125 I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 884-893.	0.8	63
80	Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate. <i>American Journal of Roentgenology</i> , 2017, 209, 339-349.	2.2	63
81	Phase 2 Study of ^{99m} Tc-Trofolostat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1408-1413.	5.0	63
82	Generalizability of established prostate cancer risk variants in men of African ancestry. <i>International Journal of Cancer</i> , 2015, 136, 1210-1217.	5.1	62
83	A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1549-1557.	2.5	61
84	Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. <i>Clinical Cancer Research</i> , 2021, 27, 4221-4229.	7.0	61
85	PSA Bounce and Biochemical Failure After Brachytherapy for Prostate Cancer: A Study of 820 Patients With a Minimum of 3 Years of Follow-Up. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 735-741.	0.8	60
86	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	1.9	60
87	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	6.3	59
88	Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). <i>Cancer Prevention Research</i> , 2014, 7, 886-895.	1.5	58
89	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	57
90	Neoadjuvant docetaxel treatment for locally advanced prostate cancer. <i>Cancer</i> , 2007, 110, 1248-1254.	4.1	55

#	ARTICLE	IF	CITATIONS
91	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1050-1058.	2.5	55
92	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>European Urology</i> , 2018, 73, 168-175.	1.9	53
93	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 399-405.	3.9	53
94	ERG rearrangement is present in a subset of transition zone prostatic tumors. <i>Modern Pathology</i> , 2010, 23, 1499-1506.	5.5	52
95	Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 871-876.	0.8	51
96	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. <i>Human Molecular Genetics</i> , 2015, 24, 5603-5618.	2.9	50
97	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	12.8	50
98	The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. <i>Cancers</i> , 2021, 13, 3501.	3.7	50
99	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study. <i>Journal of Clinical Oncology</i> , 2018, 36, 12021-12021.	1.6	50
100	Jejunal Conduit Urinary Diversion. <i>Journal of Urology</i> , 1986, 135, 244-246.	0.4	47
101	Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 1241-1244.	0.8	47
102	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. <i>Oncotarget</i> , 2017, 8, 18949-18967.	1.8	47
103	The Specific Definition of High Risk Prostate Cancer Has Minimal Impact on Biochemical Relapse-Free Survival. <i>Journal of Urology</i> , 2009, 181, 75-80.	0.4	46
104	Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 960-964.	0.8	46
105	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 471.	7.1	46
106	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 320-329.	7.0	46
107	Tumor Volume Does Not Predict for Biochemical Recurrence After Radical Prostatectomy in Patients with Surgical Gleason Score 6 or Less Prostate Cancer. <i>Urology</i> , 2007, 70, 294-298.	1.0	45
108	A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 962-975.	0.8	45

#	ARTICLE	IF	CITATIONS
109	Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. <i>Journal of Urology</i> , 2021, 205, 441-443.	0.4	44
110	Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened. <i>Journal of Urology</i> , 2014, 192, 379-384.	0.4	43
111	A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer. <i>Urology</i> , 2014, 83, 592-598.	1.0	43
112	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1777-1786.	7.0	42
113	Impact of using 29MHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. <i>World Journal of Urology</i> , 2020, 38, 1201-1206.	2.2	42
114	Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. <i>Urology</i> , 2003, 61, 152-155.	1.0	40
115	A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1347-1350.	0.8	40
116	HOXB13 Mutation and Prostate Cancer: Studies of Siblings and Aggressive Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 675-680.	2.5	40
117	Chemoprevention of Prostate Cancer. <i>Annual Review of Medicine</i> , 2006, 57, 49-63.	12.2	39
118	Priapism Associated with the Use of Intravenous Fat Emulsion: Case Reports and Postulated Pathogenesis. <i>Journal of Urology</i> , 1985, 133, 857-859.	0.4	38
119	Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. <i>Urology</i> , 2003, 62, 70-74.	1.0	38
120	Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancer-Specific Mortality by Nomogram-predicted Risks of Biochemical Recurrence. <i>European Urology</i> , 2015, 67, 204-209.	1.9	38
121	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. <i>JAMA Ophthalmology</i> , 2015, 133, 17.	2.5	38
122	Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance. <i>Journal of Urology</i> , 2020, 203, 311-319.	0.4	38
123	RACE AS AN INDEPENDENT PREDICTOR OF OUTCOME AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 1999, 162, 1331-1336.	0.4	37
124	IFNL4 G Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5471-5481.	7.0	37
125	Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers. <i>Cancer</i> , 2019, 125, 391-397.	4.1	37
126	EDITORIAL: TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY-DEFINING A NEW STANDARD. <i>Journal of Urology</i> , 2000, 163, 179-180.	0.4	36

#	ARTICLE	IF	CITATIONS
127	Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance. <i>Journal of Urology</i> , 2017, 198, 591-599.	0.4	36
128	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	3.9	36
129	Replication linkage study for prostate cancer susceptibility genes. <i>Prostate</i> , 2000, 45, 106-114.	2.3	35
130	The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. <i>European Urology</i> , 2017, 72, 942-949.	1.9	35
131	Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. <i>Clinical Cancer Research</i> , 2017, 23, 6351-6362.	7.0	35
132	The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1896-1906.	4.1	34
133	Long-Term (10-Year) Gastrointestinal and Genitourinary Toxicity after Treatment with External Beam Radiotherapy, Radical Prostatectomy, or Brachytherapy for Prostate Cancer. <i>Prostate Cancer</i> , 2012, 2012, 1-7.	0.6	33
134	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017, 197, 122-128.	0.4	33
135	The Le Bag Orthotopic Urinary Diversion. <i>Journal of Urology</i> , 1996, 156, 926-930.	0.4	32
136	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020, 78, 316-320.	1.9	32
137	A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. <i>EBioMedicine</i> , 2021, 63, 103163.	6.1	32
138	Genetic susceptibility and oxidative stress in prostate cancer: Integrated model with implications for prevention. <i>Urology</i> , 2006, 68, 1145-1151.	1.0	30
139	Introduction to Big Data in Radiation Oncology: Exploring Opportunities for Research, Quality Assessment, and Clinical Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 871-872.	0.8	30
140	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. <i>PLoS ONE</i> , 2015, 10, e0117574.	2.5	29
141	Prostate cancer screening practices in a large, integrated health system: 2007-2014. <i>BJU International</i> , 2017, 120, 257-264.	2.5	29
142	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017, 8, 50804-50813.	1.8	29
143	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	29
144	Phase III Prostate Cancer Prevention Trials: Are the Costs Justified?. <i>Journal of Clinical Oncology</i> , 2005, 23, 8161-8164.	1.6	28

#	ARTICLE	IF	CITATIONS
145	Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal cell carcinoma. <i>International Journal of Cancer</i> , 1993, 53, 941-947.	5.1	26
146	Effects of Patient Centered Interventions on Persistent Urinary Incontinence after Prostate Cancer Treatment: A Randomized, Controlled Trial. <i>Journal of Urology</i> , 2015, 194, 1675-1681.	0.4	26
147	Localized prostate cancer: radiation or surgery?. <i>Urologic Clinics of North America</i> , 2003, 30, 315-330.	1.8	25
148	External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 304-317.	0.8	25
149	Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.. <i>Journal of Urology</i> , 2021, 206, 785-785.	0.4	25
150	Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. <i>Free Radical Biology and Medicine</i> , 2016, 95, 349-356.	2.9	24
151	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	7.0	24
152	Defective DNA repair genes in a primary culture of human renal cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2000, 126, 185-190.	2.5	23
153	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. <i>European Radiology</i> , 2019, 29, 4861-4870.	4.5	23
154	Modified apical dissection for early continence after radical prostatectomy. <i>Prostate</i> , 1993, 22, 217-223.	2.3	22
155	Dynamic Contrast Enhanced Magnetic Resonance Imaging Improves Classification of Prostate Lesions: A Study of Pathological Outcomes on Targeted Prostate Biopsy. <i>Journal of Urology</i> , 2017, 198, 1301-1308.	0.4	22
156	Atypical intraductal proliferation detected in prostate needle biopsy is a marker of unsampled intraductal carcinoma and other adverse pathological features: a prospective clinicopathological study of 62 cases with emphasis on pathological outcomes. <i>Histopathology</i> , 2019, 75, 346-353.	2.9	22
157	Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. <i>Oncotarget</i> , 2016, 7, 33855-33865.	1.8	22
158	The Importance of Serum Prostate-specific Antigen Testing Frequency in Assessing Biochemical and Clinical Failure After Prostate Cancer Treatment. <i>Urology</i> , 2010, 75, 467-471.	1.0	21
159	The world's first single-room proton therapy facility: Two-year experience. <i>Practical Radiation Oncology</i> , 2017, 7, e71-e76.	2.1	21
160	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 557-567.	6.3	21
161	Avoiding Androgen Deprivation Therapy in Men With High-risk Prostate Cancer: The Role of Radical Prostatectomy as Initial Treatment. <i>Urology</i> , 2011, 77, 946-950.	1.0	20
162	Neoadjuvant Androgen Deprivation Therapy Leads to Immediate Impairment of Vitality/Hormonal and Sexual Quality of Life: Results of a Multicenter Prospective Study. <i>Urology</i> , 2013, 82, 1363-1369.	1.0	20

#	ARTICLE	IF	CITATIONS
163	Surgical management of high-risk, localized prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 679-690.	3.8	20
164	Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 846.e9-846.e16.	1.6	20
165	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	20
166	2131 DEVELOPMENT AND VALIDATION OF THE BIOPSY-BASED GENOMIC PROSTATE SCORE (GPS) AS A PREDICTOR OF HIGH GRADE OR EXTRACAPSULAR PROSTATE CANCER TO IMPROVE PATIENT SELECTION FOR ACTIVE SURVEILLANCE. <i>Journal of Urology</i> , 2013, 189, .	0.4	19
167	Applying precision medicine to the active surveillance of prostate cancer. <i>Cancer</i> , 2015, 121, 3403-3411.	4.1	19
168	Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. <i>European Urology Oncology</i> , 2018, 1, 143-148.	5.4	19
169	Clinical Models for Testing Chemopreventative Agents in Prostate Cancer and Overview of SELECT: The Selenium and Vitamin E Cancer Prevention Trial. <i>Recent Results in Cancer Research</i> , 2003, 163, 212-225.	1.8	19
170	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. <i>Journal of Urology</i> , 2019, 202, 247-255.	0.4	19
171	Management of Renal Cell Carcinoma with Coexistent Renal Artery Disease. <i>Journal of Urology</i> , 1993, 150, 808-813.	0.4	18
172	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	2.5	18
173	Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. <i>Journal of Urology</i> , 2017, 197, 376-384.	0.4	18
174	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
175	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	1.9	18
176	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. <i>American Journal of Human Genetics</i> , 2021, 108, 564-582.	6.2	18
177	Influence of Enema and Dietary Restrictions on Prostate MR Image Quality: A Multireader Study. <i>Academic Radiology</i> , 2022, 29, 4-14.	2.5	18
178	Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 192-199.	2.5	18
179	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
180	Moving a randomized clinical trial into an observational cohort. <i>Clinical Trials</i> , 2013, 10, 131-142.	1.6	17

#	ARTICLE	IF	CITATIONS
181	Rapid and structure-specific cellular uptake of selected steroids. PLoS ONE, 2019, 14, e0224081.	2.5	17
182	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	3.9	17
183	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	17
184	A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. Respiratory Research, 2015, 16, 35.	3.6	16
185	Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. Practical Radiation Oncology, 2015, 5, e437-e442.	2.1	16
186	Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European Urology, 2016, 70, 1.	1.9	16
187	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
188	Genome-wide cell-free DNA (cfDNA) methylation signatures and effect on tissue of origin (TOO) performance.. Journal of Clinical Oncology, 2019, 37, 3049-3049.	1.6	16
189	Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma. Clinical Cancer Research, 2008, 14, 3052-3059.	7.0	15
190	A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2018, 15, 1293-1299.	0.6	15
191	Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low-dose rate brachytherapy monotherapy. Brachytherapy, 2020, 19, 43-50.	0.5	15
192	A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer and Prostatic Diseases, 2021, 24, 733-742.	3.9	14
193	Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. Journal of Urology, 2021, 206, 1147-1156.	0.4	14
194	Retained Straight Catheter: Complication of Clean Intermittent Catheterization. Journal of Urology, 1986, 135, 780-781.	0.4	13
195	Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate. Urology, 2006, 68, 1237-1241.	1.0	13
196	More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2016, 195, 1767-1772.	0.4	13
197	Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?. BJU International, 2019, 124, 282-289.	2.5	13
198	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. Npj Precision Oncology, 2021, 5, 35.	5.4	13

#	ARTICLE	IF	CITATIONS
199	Clinical Validation of IsoPSA [®] , a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 1115-1120.	0.4	13
200	Future Directions From Past Experience: A Century of Prostate Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 13-20.	1.9	12
201	For Single Dosing, Levofloxacin Is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy. <i>Urology</i> , 2015, 85, 1241-1246.	1.0	12
202	Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 617-623.	0.8	12
203	Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 559-566.	2.6	12
204	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
205	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	1.9	12
206	Functional Equivalence of End and Loop Ileal Conduit Stomas. <i>Journal of Urology</i> , 1992, 147, 582-586.	0.4	11
207	Intermediate-Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience. <i>Prostate Journal</i> , 2001, 3, 118-125.	0.2	11
208	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016, 96, 116-120.	1.0	11
209	Consensus guidelines for reporting prostate cancer Gleason Grade. <i>BJU International</i> , 2016, 117, 849-849.	2.5	11
210	Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance. <i>Journal of Urology</i> , 2018, 199, 438-444.	0.4	11
211	Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 435-440.	3.9	11
212	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	1.0	11
213	Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 748-753.	0.4	11
214	The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. <i>Diagnostics</i> 2021, 11, 2171. <i>Diagnostics</i> , 2022, 12, 1243.	2.6	11
215	Consensus guidelines for reporting prostate cancer Gleason Grade. <i>BJU International</i> , 2016, 118, E1-2.	2.5	10
216	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10

#	ARTICLE	IF	CITATIONS
217	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 292-302.	3.9	10
218	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. <i>JCO Precision Oncology</i> , 2021, 5, 442-449.	3.0	10
219	Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy. <i>Cancer</i> , 2021, 127, 1425-1431.	4.1	10
220	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.7	10
221	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for cribriform prostatic adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1092-1100.	5.5	10
222	Noninvasive Testicular Screening in Childhood Leukemia. <i>Journal of Urology</i> , 1986, 136, 864-866.	0.4	9
223	New Gleason grading system: Statement from the Editors of six journals. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 253.	1.6	9
224	Stage Grouping. <i>Journal of Urology</i> , 2016, 195, 1723-1723.	0.4	9
225	Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. <i>Urology</i> , 2016, 93, 1.	1.0	9
226	Prognostic Significance of a Negative Confirmatory Biopsy on Reclassification Among Men on Active Surveillance. <i>Urology</i> , 2017, 107, 184-189.	1.0	9
227	Is a behavioral treatment for urinary incontinence beneficial to prostate cancer survivors as a follow-up care?. <i>Journal of Cancer Survivorship</i> , 2017, 11, 24-31.	2.9	9
228	Impact of 5 α -Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. <i>Journal of Urology</i> , 2018, 199, 445-452.	0.4	9
229	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1376-1383.	2.5	9
230	A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3070-3070.	1.6	9
231	Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. <i>Journal of Urology</i> , 2020, 203, 115-119.	0.4	9
232	Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy. <i>Journal of Urology</i> , 2017, 197, 84-89.	0.4	8
233	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. <i>Oncogene</i> , 2019, 38, 4496-4511.	5.9	8
234	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	2.5	8

#	ARTICLE	IF	CITATIONS
235	Prognostic value of the SPOP mutant genomic subclass in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 418-422.	1.6	8
236	SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 952-958.	0.4	8
237	Acute Complications after Radical Retropubic Prostatectomy. <i>Prostate Journal</i> , 2000, 2, 22-26.	0.2	7
238	Early infectious complications with transponder placement for external beam radiation therapy for prostate cancer. <i>BJU International</i> , 2012, 110, 834-838.	2.5	7
239	Molecular markers in urologic oncology. <i>Current Opinion in Urology</i> , 2016, 26, 225-230.	1.8	7
240	Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. <i>Clinical Epigenetics</i> , 2019, 11, 168.	4.1	7
241	Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1047-1054.	0.4	7
242	5 α -Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis. <i>Journal of Urology</i> , 2022, 207, 183-189.	0.4	7
243	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022, 40, 19-26.	0.4	7
244	Retroviral transduction of intercellular adhesion molecule-1 enhances endothelial attachment of bladder cancer. <i>Urological Research</i> , 1997, 25, 401-405.	1.5	6
245	MR-TRUS fusion biopsy—defining a new standard. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 253-254.	27.6	6
246	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. <i>EBioMedicine</i> , 2016, 7, 85-93.	6.1	6
247	Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. <i>BJU International</i> , 2017, 119, 961-967.	2.5	6
248	Robotic Single-port Partial Prostatectomy for Anterior Tumors: Transvesical Approach. <i>Urology</i> , 2018, 118, 242.	1.0	6
249	Editorial: Can Prostate Specific Antigen Derivatives Reduce the Frequency of Unnecessary Prostate Biopsies?. <i>Journal of Urology</i> , 1996, 156, 443-444.	0.4	5
250	Does cumulative prostate cancer length (<scp>CCL</scp>) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?. <i>BJU International</i> , 2015, 116, 220-229.	2.5	5
251	Seeing and Not Believing: Oligometastases and the Future of Metastatic Prostate Cancer. <i>European Urology</i> , 2015, 67, 864-865.	1.9	5
252	Outcomes for prostate glands >60cc treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 163-168.	0.5	5

#	ARTICLE	IF	CITATIONS
253	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. <i>Urology</i> , 2018, 121, 132-138.	1.0	5
254	A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy. <i>Urology</i> , 2019, 129, e4-e5.	1.0	5
255	The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5574-5574.	1.6	5
256	Transperineal Prostate Biopsy is Associated With Lower Tissue Core Pathogen Burden Relative to Transrectal Biopsy: Mechanistic Underpinnings for Lower Infection Risk in the Transperineal Approach. <i>Urology</i> , 2022, , .	1.0	5
257	SARCOMATOID TRANSITIONAL CELL CARCINOMA OF BLADDER MANAGED WITH TRANSURETHRAL RESECTION ALONE. <i>Journal of Urology</i> , 2002, 167, 641-642.	0.4	4
258	Reducing Overutilization of Preoperative Medical Referrals Among Patients Undergoing Radical Cystectomy Using an Evidence-based Algorithm. <i>Urology</i> , 2018, 114, 71-76.	1.0	4
259	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 199, 719-725.	0.4	4
260	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019, 125, 3853-3863.	4.1	4
261	Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 104.e1-104.e7.	1.6	4
262	Hypoxia-Reoxygenation Couples 3Î²HSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer. <i>Cancer Research</i> , 2022, 82, 2417-2430.	0.9	4
263	Clinical Investigations Prophylactic urethral stenting with MemokathÂ® 028SW in prostate cancer patients undergoing prostate 125I seed implants: phase I/II study. <i>Journal of Contemporary Brachytherapy</i> , 2011, 1, 18-22.	0.9	3
264	Re: Long-term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer. <i>European Urology</i> , 2015, 68, 906-907.	1.9	3
265	Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. <i>Nature Reviews Urology</i> , 2017, 14, 59-64.	3.8	3
266	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 459.e15-459.e24.	1.6	3
267	Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map Analysis. <i>Urology Practice</i> , 2018, 5, 383-390.	0.5	3
268	The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. <i>Cancer Epidemiology</i> , 2018, 55, 117-122.	1.9	3
269	Testing of a Tool for Prostate Cancer Screening Discussions in Primary Care. <i>Frontiers in Oncology</i> , 2018, 8, 238.	2.8	3
270	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. <i>Urology</i> , 2019, 130, 106-112.	1.0	3

#	ARTICLE	IF	CITATIONS
271	125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. <i>Brachytherapy</i> , 2022, 21, 85-93.	0.5	3
272	Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 408.e9-408.e18.	1.6	3
273	Genetics of transitional cell carcinoma. <i>Journal of Surgical Oncology</i> , 1992, 8, 260-266.	1.4	2
274	Editorial: Prostate Cancer. <i>Journal of Urology</i> , 1995, 154, 143-144.	0.4	2
275	Prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 494.	1.6	2
276	Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial. <i>Trials</i> , 2016, 17, 400.	1.6	2
277	Editorial Statement on Gleason Scoring for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1092.	0.8	2
278	Addition of magnetic resonance imaging to real time trans-rectal ultrasound-based treatment planning for prostate implants. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 361-369.	0.9	2
279	Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 617-623.	3.9	2
280	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	3.0	2
281	Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 469-476.	1.3	2
282	Suprapubic Approach for Bilateral Orchiectomy and Placement of Testicular Prostheses. <i>Journal of Urology</i> , 1990, 143, 765-766.	0.4	1
283	Radical prostatectomy versus watchful waiting for early prostate cancer: finally, an answer. <i>Nature Reviews Urology</i> , 2005, 2, 412-413.	1.4	1
284	Influence of zonal dosimetry on prostate brachytherapy outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2015, 1, 17-22.	0.9	1
285	Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 366-372.	1.9	1
286	Perioperative Troponin is a Predictor of Both Short- and Intermediate-term Mortality Among Patients Undergoing Major Urologic Surgery. <i>Urology</i> , 2019, 123, 108-113.	1.0	1
287	The Association of Urologic Oncology Fellowship Training and Diagnostic Yield of Prostate Biopsy. <i>Urology</i> , 2020, 137, 115-120.	1.0	1
288	Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. , 2021, 5, 50-61.		1

#	ARTICLE	IF	CITATIONS
289	Pitfalls in Prostate MRI Interpretation: A Pictorial Review. <i>Seminars in Roentgenology</i> , 2021, 56, 391-405.	0.6	1
290	Elevated IsoPSA Selects for Clinically Significant Prostate Cancer Without a Preference for Any Particular Adverse Histopathologic or Radiographic Feature.. <i>Urology</i> , 2022, , .	1.0	1
291	Detection of Clinically Significant Index Prostate Cancer Using Micro-ultrasound: Correlation With Radical Prostatectomy. <i>Urology</i> , 2022, 169, 150-155.	1.0	1
292	Safety of Transurethral Surgery in the Early Postoperative Period Following an Open Cardiac Procedure. <i>Journal of Urology</i> , 1994, 151, 902-904.	0.4	0
293	SUBTOTAL RADICAL CYSTECTOMY AFTER RADICAL PROSTATECTOMY: A SOURCE OF PELVIC RECURRENCE OF BLADDER CANCER WITH LIFE THREATENING BLEEDING. <i>Journal of Urology</i> , 2001, 166, 988-989.	0.4	0
294	Is histologic necrosis in the primary tumor of patients with renal-cell carcinoma a predictor for survival?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 72-73.	4.3	0
295	In Reply to Samaratunga etÂal. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1127-1128.	0.8	0
296	Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. <i>Urology</i> , 2016, 96, 179.	1.0	0
297	A Case of Prostate Cancer in Lynch Syndrome. <i>Urology</i> , 2016, 95, 25-28.	1.0	0
298	Effects of Castration on BPH. <i>Journal of Urology</i> , 2017, 197, S76-S77.	0.4	0
299	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1040-1040.	0.4	0
300	A 72-Year-Old Man With Obstructive Voiding Symptoms, Elevated Prostate-specific Antigen Level, and Nodular Digital Rectal Examination. <i>Urology</i> , 2017, 104, 22-24.	1.0	0
301	Reply to Bahram Habibzadeh and Farrokh Habibzadeh's Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. <i>Eur Urol</i> 2017;72:942â€“9. The Most Appropriate IsoPSA Cutoff for Diagnosis of Prostate Cancer. <i>European</i>	1.9	0
302	Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. <i>Eur Urol</i> 2016;70:1. <i>European Urology</i> , 2017, 71, e54.	1.9	0
303	Gene Expression Testing as a Predictor of Adverse Pathology after Radical Prostatectomy: Implications for Choosing Patients for Active Surveillance. <i>Urology Practice</i> , 2017, 4, 140-148.	0.5	0
304	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 1474-1474.	0.4	0
305	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 572-572.	0.4	0
306	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 460-460.	0.4	0

#	ARTICLE	IF	CITATIONS
307	Management of a Prostate Cancer Patient With Inherited Germline BRCA1 and BRCA2 Mutations: A Case Report. <i>Urology</i> , 2021, 153, 129-131.	1.0	0
308	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1156.	0.4	0
309	Reply by Authors. <i>Journal of Urology</i> , 2022, 207, 189.	0.4	0
310	Impact of different definitions of high-risk prostate cancer on survival after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 113-113.	1.6	0
311	OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 93-93.	1.6	0
312	Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 51-51.	1.6	0
313	Tissue-Based Markers for Risk Prediction. <i>Current Clinical Urology</i> , 2018, , 121-133.	0.0	0
314	PSA screening: Back to the future. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 881-883.	1.3	0
315	Radiomic features derived from pre-operative multi-parametric MRI of prostate cancer are associated with Decipher risk score. , 2019, , .		0
316	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 101-101.	0.4	0
317	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 701-701.	0.4	0
318	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 958-958.	0.4	0
319	A Rational Approach to Managing Prostate Cancer in an Irrational Time. <i>Oncology</i> , 2020, , 163-163.	0.5	0
320	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 318-319.	0.4	0
321	Multicancer early detection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, .	2.3	0